717133-25-0

Basic information

• Product Name: 4-[4-(Dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)benzonitrile hydrochloride
• Synonyms: 4-[4-(Dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)benzonitrile hydrochloride;4-(4-(Dimethylamino)-1-(4-fluorophenyl)-1-hydroxy-butyl)-3-(hydroxymethyl)benzonitrile hydrochlor;4-(4-(Dimethylamino)-1-(4-fluorophenyl)-1-hydroxy-butyl)-3-(hydroxymethyl)benzonitrile hydroch;4-[4-DIMETHYLAMINO)-1-(4-FLUOROPHENYL)-1-HYDROCY-1BUTYL]-3 HYDROXYMETHYLBENZONITRILE HYDROBROMIDE
• CAS NO: 717133-25-0
• Molecular Formula: C₂₀H₂₃FN₂O₂*ClH
• Molecular Weight: 378.87
• Mol File: 717133-25-0.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 4-[4-(Dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)benzonitrile hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[4-(Dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)benzonitrile hydrochloride(717133-25-0)
• EPA Substance Registry System: 4-[4-(Dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)benzonitrile hydrochloride(717133-25-0)

Safety Data

• Hazardous Substances Data: 717133-25-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
4-[4-(Dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)benzonitrile hydrochloride is utilized as a chemical intermediate in the synthesis of potential therapeutic agents, given its unique structural features that may confer specific biological activities. Its improved solubility and stability due to the hydrochloride salt form facilitate its use in laboratory settings for the exploration of new drug candidates.
Further research is necessary to elucidate the full spectrum of properties and potential applications of this chemical, including its role in the treatment of various medical conditions. As it stands, the compound's use is primarily confined to the realm of pharmaceutical research, where its unique structural elements are investigated for possible therapeutic benefits.

InChI:InChI=1/C20H23FN2O2.ClH/c1-23(2)11-3-10-20(25,17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24;/h4-9,12,24-25H,3,10-11,14H2,1-2H3;1H

Upstream product

• 19070-16-7 3-(N,N-dimethylamino)propylmagnesium chloride 
• 82104-74-3 1-oxo-1,3-dihydro-isobenzofuran-5-carbonitrile 
• 352-13-6 4-flourophenylmagnesium bromide 
• 96-47-9 2-methyltetrahydrofuran 

Downstream Products

• 103146-25-4 4-[4-(dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)benzonitrile 

Relevant articles and documents

METHOD FOR CONTINUOUSLY PREPARING CITALOPRAM DIOL

The present application relates to a method for citalopram intermediate citalopram diol. The method comprises: first mixing two Grignard reagents required for a reaction; then mixing the mixed Grignard reagents with a raw material 5-cyanophthalide in a te

CRYSTALLINE CITALOPRAM DIOL INTERMEDIATE ALKALI

The present invention relates to the diol intermediate of citalopram useful for treatment of depression, that is to say, the crystal of free alkali of 3-hydroxylmethyl-4-[1-(4-fluorophenyl)-1-hydroxyl-4-(dimethylamino)] butylbenzonitrile and the method of crystallization thereof. The present invention has disclosed the method to prepare pure citalopram and its purified salts through crystallization of the described alkali;the optical resolution method of citalopram diol intermediate, the method to prepare S-citalopram and its purified salts by crystals mentioned above. The present invention has also disclosed the method to prepare citalopram and its purified salts, S-citalopram and its purified salts, as well as pharmaceutical formulation thereof obtained. Using methods of the present invention, the quality and yield of the product can be signally improved, and the production cost of the medicinal material can be decreased.